Deals

cardiovascular disease
Biotech

Novo calls off $598M Heartseed collab, citing 'strategic reviews'

Japanese biotech Heartseed said it was "difficult to reasonably foresee" that Novo would scrap the 2021 deal, despite the pharma's restructuring.
Zoey Becker Sep 30, 2025 1:55pm
Metallic arrow symbols which are illuminated by blue and magenta lights merge on blue and magenta b

Barinthus enters reverse merger with metabolic disease biotech

Sep 30, 2025 10:39am
direction arrow

Anaptys plans to split into 2 businesses

Sep 30, 2025 9:35am
viking ship long boat chase race water sunset

BioLineRx forges joint cancer venture with Norwegian biotech

Sep 29, 2025 11:22am
Glowing puzzle piece fitting into puzzle

Gilead pumps up virology pipeline with drug transporter deal

Sep 29, 2025 10:35am
MA strategy deal block push come together form

Genmab pays $8B to buy Merus and phase 3 bispecific

Sep 29, 2025 5:38am